HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Proto-Oncogene Proteins c-mdm2

Subscribe to New Research on Proto-Oncogene Proteins c-mdm2

An E3 UBIQUITIN LIGASE that interacts with and inhibits TUMOR SUPPRESSOR PROTEIN P53. Its ability to ubiquitinate p53 is regulated by TUMOR SUPPRESSOR PROTEIN P14ARF.

Also Known As:

Double Minute 2 Protein; MDMX Protein; Mdm-2 Protein; Murine Double Minute 2 Protein; Mdm 2 Protein; Proto Oncogene Proteins c mdm2; Proto-Oncogene Protein, c-mdm2; c mdm2 Proto Oncogene Protein; c-mdm2, Proto-Oncogene Proteins; Mdm2 Protein; c-mdm2 Proto-Oncogene Protein

Networked: 209 relevant articles (0 outcomes, 34 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Patil, Sachin P: 4 articles (02/2015 - 12/2013)
2.	Zhang, Ruiwen: 3 articles (02/2015 - 09/2005)
3.	Wang, Hui: 3 articles (02/2015 - 09/2005)
4.	Eischen, Christine M: 2 articles (12/2015 - 02/2002)
5.	Jin, Lixia: 2 articles (03/2015 - 04/2014)
6.	Zhou, Jing: 2 articles (03/2015 - 04/2014)
7.	Chen, Ada: 2 articles (03/2015 - 04/2014)
8.	Osgood, Tao: 2 articles (03/2015 - 04/2014)
9.	Yu, Dongyin: 2 articles (03/2015 - 04/2014)
10.	Ye, Qiuping: 2 articles (03/2015 - 04/2014)

Related Diseases

1.	Neoplasms (Cancer) 02/15/2001 - "Therefore, this protein needs to be strictly regulated and numerous studies have shown that the MDM2 protein is an essential element for p53 regulation in normal cells and, most importantly, that overexpression of MDM2 is responsible for p53 inactivation in various types of tumors. " 12/01/2015 - "Targeting the murine double minute 2 (Mdm2) protein is an attractive approach, as Mdm2 levels are elevated in many therapy-refractive breast cancers. " 08/27/2015 - "As a result of our efforts to discover novel p53:MDM2 protein-protein interaction inhibitors useful for treating cancer, the potent and selective MDM2 inhibitor NVP-CGM097 (1) with an excellent in vivo profile was selected as a clinical candidate and is currently in phase 1 clinical development. " 03/01/2015 - "AMG 232 binds the MDM2 protein with picomolar affinity and robustly induces p53 activity, leading to cell-cycle arrest and inhibition of tumor cell proliferation. " 02/20/2015 - "Furthermore, JapA directly bound to MDM2 protein and reduced MDM2 levels in cancer cells in vitro and in vivo by promoting MDM2 protein degradation and inhibiting MDM2 transcription, which is distinct from the existing MDM2 inhibitors. "
2.	Carcinoma (Carcinomatosis) 01/01/2006 - "The present study was performed to evaluate the relationship between MDM2 protein expression and survival in breast carcinoma. " 11/01/1998 - "In this study the expression of mdm2 protein has been investigated in a series of 54 human breast carcinomas using immunoblotting methods. " 03/01/1997 - "This study showed the expression of ER to be associated with MDM2 protein in p53 protein negative breast carcinoma. " 05/01/1995 - "The present study reports on the frequency of MDM2 gene amplification and MDM2 protein expression in a series of 100 breast carcinomas and its association with accumulation of the p53 protein. " 01/01/2006 - "MDM2 protein expression is a negative prognostic marker in breast carcinoma."
3.	Glioma (Gliomas) 05/01/2007 - "In our study population, SNP309 affected MDM2 protein level, but had no significant involvement in glioma tumorigenesis." 05/01/2007 - "Immunohistochemical study of glioma tissues showed that the G/G genotype was associated with higher expression of MDM2 protein compared to the T/T genotype, suggesting that SNP309 attenuates MDM2 protein expression in vivo. " 08/01/2011 - "The overexpression of MDM-2 protein was an early event in malignant transformation of glioma. " 08/01/2011 - "Overexpression of MDM-2 protein may play an important role in glioma tumorigenesis, but may not be involved in glioma progression. " 08/01/2011 - "The expression of P53 protein was not related to expression of MDM-2 protein (P = 0.069) Overexpression of P53 protein might be related to the occurrence and progression of glioma. "
4.	Sarcoma (Soft Tissue Sarcoma) 11/01/1998 - "The aim of this study was the evaluation of p53/MDM-2 protein overexpression in different subtypes of human sarcomas, and their correlation with proliferative activity and patient outcome. " 01/01/1994 - "Immunohistochemical studies investigating the quantity of MDM2 protein in human sarcomas revealed an overexpression in 30% of the specimens. " 05/01/2003 - "No p21 was found; and the 76 kDa MDM2 protein was demonstrated in 18% (6/33) of the sarcomas. " 03/26/1998 - "Mdm2 gene amplification has been described in several types of sarcomas, resulting in overexpression of the MDM2 protein. " 11/01/1995 - "Overexpression of only the p90 MDM-2 protein has been reported in sarcomas showing MDM-2 gene amplification. "
5.	Prostatic Neoplasms (Prostate Cancer) 09/01/2012 - "To determine the risk, malignant degree and clinical progression of prostate cancer (PCa) associated with mouse double-minute 2 protein (MDM2) T309G variants, a meta-analysis was performed on all eligible published studies. " 01/01/2009 - "In this study, we attempted to determine if the MDM2 SNP309 polymorphism plays a role in the aggressive phenotype seen in African American (AA) prostate cancer by examining the association between MDM2 SNP309 and MDM2 protein levels in prostate cancer (PCa) patients of different racial backgrounds. " 09/15/2005 - "In a dose- and time-dependent manner, genistein reduced MDM2 protein and mRNA levels in human cell lines of breast, colon, and prostate cancer; primary fibroblasts; and breast epithelial cells. " 03/01/2007 - "In a human prostate cancer cell lines PC3 (p53(null)), curcumin reduced MDM2 protein and mRNA in a dose- and time-dependent manner, and enhanced the expression of the tumor suppressor p21(Waf1/CIP1). " 05/15/2008 - "Exposure of human prostate cancer 22Rv1 cells, harboring wild-type p53, to growth-suppressive concentrations (10-80 microM) of apigenin resulted in the stabilization of p53 by phosphorylation on critical serine sites, p14ARF-mediated downregulation of MDM2 protein, inhibition of NF-kappaB/p65 transcriptional activity, and induction of p21/WAF-1 in a dose- and time-dependent manner. "

Related Drugs and Biologics

1.	Antibodies
2.	Proteins (Proteins, Gene)
3.	RNA (Ribonucleic Acid)
4.	Tumor Suppressor Protein p14ARF (p14ARF)
5.	Messenger RNA (mRNA)
6.	Cyclin-Dependent Kinase Inhibitor p16
7.	Serine (L-Serine)
8.	DNA (Deoxyribonucleic Acid)
9.	Carbon Monoxide
10.	NF-kappa B (NF-kB)

Related Therapies and Procedures

1.	Therapeutics
2.	Heterologous Transplantation (Xenotransplantation)
3.	Radiotherapy